Company intelligence / Profile preview
Qingdao Primedicine Pharmaceutical Technology Co., Ltd.
Qingdao, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed preclinical research on drug addiction and cerebral stroke indications as of 2020; preparing for Phase 1.
- Therapeutic areas
- PsychiatryCardiovascularNeurology
- Modalities
- Peptides
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Primary Peptides Inc. (exclusive license for China on myocardial infarction peptide)
Beyond the preview
Go deeper on Qingdao Primedicine Pharmaceutical Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qingdao Primedicine Pharmaceutical Technology Co., Ltd..